ArticleNeurological research and practice2026
Longitudinal changes of serum immunoglobulins under ocrelizumab: factors associated with hypogammaglobulinemia and infection risk in a real-world multiple sclerosis cohort.
Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOcrelizumab (OCR) is an effective anti-CD20 therapy for relapsing-remitting and primary progressive multiple sclerosis (MS), but long-term effects on humoral immunity in real-world settings remain incompletely characterized. We investigated longitudinal changes in serum immunoglobulins, explored factors associated with hypogammaglobulinemia, and assessed associations with infection risk.
methodsIn this retrospective, single-center observational study, adult patients with MS treated with OCR between 2018 and 2023 were included after ≥ 2 treatment cycles. Patients underwent standardized clinical, radiological, and laboratory follow-up, including serial measurements of serum immunoglobulins and varicella-zoster virus (VZV) serology. Infections were graded according to CTCAE criteria.
resultsOf 116 patients (81% relapsing-remitting MS; median follow-up 2.3 years), approximately one-third developed lower limit of normal (LLN) IgM and one-sixth LLN IgG. Declines in immunoglobulins were class-specific and treatment-duration-dependent, most pronounced for IgM. Low baseline immunoglobulin levels were the strongest factors associated with LLN values, whereas demographic and disease-related factors were not. Prior immunotherapy, particularly fingolimod or interferon, was associated with hypogammaglobulinemia. Severe infections were rare (1.1 per 100 patient-years) and not consistently associated with LLN immunoglobulins. DISCUSSION: OCR induced predictable, class-specific declines in immunoglobulins. Despite frequent hypogammaglobulinemia - particularly affecting IgM - no association with an increased short- to mid-term risk of clinically relevant infections was observed, although limited event numbers restrict conclusions. These findings support individualized immunoglobulin monitoring focused on patients with low baseline levels or prior immunotherapy exposure and underscore the need for prospective studies to define clinically meaningful thresholds for intervention during long-term anti-CD20 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.